Vertex to Acquire Wave Life Sciences for $3.2B
Ticker: WVE · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1631574
| Field | Detail |
|---|---|
| Company | Wave Life Sciences Ltd. (WVE) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0, $260 million, $5 billion, $10 billion |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, biotech
Related Tickers: VRTX
TL;DR
Vertex is buying Wave Life Sciences for $3.2 BILLION, deal expected to close Q4 2024.
AI Summary
Wave Life Sciences Ltd. announced on October 11, 2024, that it has entered into a definitive agreement to be acquired by Vertex Pharmaceuticals Incorporated for approximately $3.2 billion. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition by Vertex Pharmaceuticals could significantly advance Wave Life Sciences' pipeline of RNA-based therapeutics, potentially leading to new treatments for various diseases.
Risk Assessment
Risk Level: low — The acquisition is a definitive agreement with a large, established company, indicating a high likelihood of completion.
Key Numbers
- $3.2B — Acquisition Price (Total value of the deal between Vertex Pharmaceuticals and Wave Life Sciences.)
- Q4 2024 — Expected Closing (Anticipated timeframe for the completion of the acquisition.)
Key Players & Entities
- Wave Life Sciences Ltd. (company) — Company filing the report and being acquired
- Vertex Pharmaceuticals Incorporated (company) — Acquiring company
- $3.2 billion (dollar_amount) — Acquisition price
- October 11, 2024 (date) — Date of the definitive agreement
- fourth quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary reason for Vertex Pharmaceuticals acquiring Wave Life Sciences?
While not explicitly stated as the sole reason, the acquisition is likely driven by Wave Life Sciences' pipeline of RNA-based therapeutics, which Vertex aims to advance.
What is the total value of the acquisition deal?
The definitive agreement states that Vertex Pharmaceuticals will acquire Wave Life Sciences for approximately $3.2 billion.
When is the acquisition expected to be completed?
The transaction is anticipated to close in the fourth quarter of 2024.
Are there any specific conditions that need to be met for the acquisition to close?
Yes, the acquisition is subject to customary closing conditions.
What type of therapeutics does Wave Life Sciences specialize in?
Wave Life Sciences focuses on RNA-based therapeutics.
Filing Stats: 701 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-10-15 17:15:29
Key Financial Figures
- $0 — of each exchange on which registered $0 Par Value Ordinary Shares WVE The N
- $260 million — ion, Takeda has paid Wave approximately $260 million. As a result of the Option Terminatio
- $5 billion — s. WVE-003 alone represents a potential $5 billion commercial opportunity, with potential
- $10 billion — pportunity, with potential to expand to $10 billion with programs targeting other single nu
Filing Documents
- d899308d8k.htm (8-K) — 25KB
- 0001193125-24-237665.txt ( ) — 145KB
- wve-20241011.xsd (EX-101.SCH) — 3KB
- wve-20241011_lab.xml (EX-101.LAB) — 18KB
- wve-20241011_pre.xml (EX-101.PRE) — 11KB
- d899308d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WAVE LIFE SCIENCES LTD. By: /s/ Kyle Moran Kyle Moran Chief Financial Officer Date: October 15, 2024